Log in

NASDAQ:CMRXChimerix Stock Price, Forecast & News

$3.16
-0.03 (-0.94 %)
(As of 07/3/2020 01:19 PM ET)
Add
Compare
Today's Range
$3.11
Now: $3.16
$3.24
50-Day Range
$2.85
MA: $3.20
$3.63
52-Week Range
$1.19
Now: $3.16
$4.23
Volume276,571 shs
Average Volume408,773 shs
Market Capitalization$195.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Read More
Chimerix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.52 million
Book Value$1.79 per share

Profitability

Net Income$-112,580,000.00
Net Margins-923.87%

Miscellaneous

Employees82
Market Cap$195.70 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

How has Chimerix's stock been impacted by COVID-19 (Coronavirus)?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CMRX stock has increased by 119.4% and is now trading at $3.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chimerix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chimerix.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chimerix.

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $1.24 million for the quarter, compared to the consensus estimate of $1.50 million. Chimerix had a negative return on equity of 34.16% and a negative net margin of 923.87%. View Chimerix's earnings history.

What price target have analysts set for CMRX?

1 brokerages have issued 1-year price targets for Chimerix's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Chimerix's stock price to reach $7.00 in the next year. This suggests a possible upside of 121.5% from the stock's current price. View analysts' price targets for Chimerix.

Has Chimerix been receiving favorable news coverage?

Press coverage about CMRX stock has trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chimerix earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Chimerix.

Are investors shorting Chimerix?

Chimerix saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,200,000 shares, a decrease of 26.8% from the May 31st total of 1,640,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 1.1 days. Approximately 2.6% of the shares of the company are sold short. View Chimerix's Current Options Chain.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
  • Mr. Michael A. Sherman, CEO & Pres (Age 53)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $3.16.

How big of a company is Chimerix?

Chimerix has a market capitalization of $195.70 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.